Background. Meta-analysis of cross-sectional genome-wide association studies (GWAS) on creatinine-estimated glomerular filtration rate (eGFR crea ) identified 53 single-nucleotide polymorphisms (SNPs). These SNP effects can be aggregated into a genetic risk score (GRS) for chronic kidney disease (CKD). To assess its clinical utility, we examined associations with creatinine-estimated kidney outcomes, both cross-sectionally and longitudinally. Additionally, we examined associations with cystatin C-estimated kidney outcomes to verify that a GRS based on eGFR crea SNPs represents the genetics underlying kidney function. Methods. In the community-based Prevention of REnal and Vascular ENdstage Disease (PREVEND) study, we assessed eGFR crea and eGFR cysc at baseline and four follow-up examinations. The GRS comprised 53 SNPs for eGFR crea weighted for reported effect-sizes. We adjusted for baseline demographics and renal risk factors. Results. We included 3649 subjects (median age 49 years, 52% male, median follow-up 11 years, n ¼ 85 baseline CKD, n ¼ 154 incident CKD). At baseline, a higher GRS associated with lower eGFR crea {adjusted B [95% confidence interval (CI)] ¼ À2.05 (À2.45 to À 1.65) mL/min/1.73 m
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Background. Meta-analysis of cross-sectional genome-wide association studies (GWAS) on creatinine-estimated glomerular filtration rate (eGFR crea ) identified 53 single-nucleotide polymorphisms (SNPs). These SNP effects can be aggregated into a genetic risk score (GRS) for chronic kidney disease (CKD). To assess its clinical utility, we examined associations with creatinine-estimated kidney outcomes, both cross-sectionally and longitudinally. Additionally, we examined associations with cystatin C-estimated kidney outcomes to verify that a GRS based on eGFR crea SNPs represents the genetics underlying kidney function. Methods. In the community-based Prevention of REnal and Vascular ENdstage Disease (PREVEND) study, we assessed eGFR crea and eGFR cysc at baseline and four follow-up examinations. The GRS comprised 53 SNPs for eGFR crea weighted for reported effect-sizes. We adjusted for baseline demographics and renal risk factors. Results. We included 3649 subjects (median age 49 years, 52% male, median follow-up 11 years, n ¼ 85 baseline CKD, n ¼ 154 incident CKD). At baseline, a higher GRS associated with lower eGFR crea {adjusted B [95% confidence interval (CI)] ¼ À2.05 (À2.45 to À 1.65) mL/min/1.73 m 2 , P < 0.001} and higher CKD prevalence [adjusted odds ratio (95% CI) ¼ 1.41 (1.12-1.77), P ¼ 0.002]. During follow-up, a higher GRS associated with higher CKD incidence [adjusted hazard ratio (95% CI) ¼ 1.28 (1.09-1.50), P ¼ 0.004], but no longer significantly after adjustment for baseline eGFR. No significant association with eGFR crea decline was found. Associations with cystatin C-estimated outcomes were similar. Conclusions. The GRS robustly associated with baseline CKD and eGFR, independent of known risk factors. Associations with incident CKD were likely due to low baseline eGFR, not accelerated eGFR decline. The GRS for eGFR crea likely represents the genetics underlying kidney function, not creatinine metabolism or underlying aetiologies. To improve the clinical utility of GWAS results for CKD, these need to specifically address eGFR decline and CKD incidence.
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I N T R O D U C T I O N
Chronic kidney disease (CKD) is a heterogeneous group of diseases defined by the presence of sustained reduced kidney function or kidney damage. Strong evidence exists for a genetic component to CKD risk: CKD has been observed to aggregate in families [1] [2] [3] and heritability estimates are reported to range between 30% and 75% [4] [5] [6] [7] [8] [9] . Furthermore, genome-wide association studies (GWAS) in populations of European ancestry have identified common genetic variants associated with CKD and kidney function markers [10] [11] [12] [13] [14] . The largest and most comprehensive genetic study is a cross-sectional meta-analysis of GWAS in which single-nucleotide polymorphisms (SNPs) at 53 loci were found to be associated with creatinine-estimated glomerular filtration rate (eGFR crea ) [15] .
The individual SNPs identified in this meta-analysis can be combined into a genetic risk score (GRS) [16] [17] [18] , which summarizes individual genetic predisposition to CKD. Such a GRS is a potentially useful tool in aetiological and predictive studies of CKD. However, because the SNPs were identified in a cross-sectional GWAS design, it is uncertain whether a GRS is associated with longitudinal outcomes. Furthermore, there is overlap between the 53 loci from the aforementioned metaanalysis and loci identified in a large GWAS on serum creatinine [11, 12] . Therefore, it is difficult to discern whether a GRS corresponds to kidney function per se or partly reflects creatinine production/secretion.
The main study aim was to evaluate the applicability of a GRS, comprising 53 SNPs identified in cross-sectional GWAS on eGFR crea , in longitudinal outcomes. To this end, we tested three hypotheses. First, we tested the hypothesis that the GRS would be associated with kidney outcomes, not only crosssectionally (i.e. with baseline CKD, baseline eGFR), but also longitudinally (i.e. with incident CKD, eGFR decline). Secondly, to assess whether the GRS is a true representation of a genetic component to kidney function, we hypothesized that the GRS would also be associated with GFR estimates not based on serum creatinine. We therefore compared the associations of the GRS with eGFR crea to those of the GRS with a serum cystatin C-estimated GFR (eGFR cysc ) [19] . Thirdly, to rule out that the GRS represents a component to kidney damage rather than kidney function, we hypothesized that the GRS would not be associated with albuminuria (i.e. urinary albumin excretion, UAE).
M A T E R I A L S A N D M E T H O D S

Study population and design
We used data from the Prevention of REnal and Vascular ENdstage Disease (PREVEND) cohort study [20] . PREVEND was initiated to investigate the natural course of increased urinary albumin levels and its association to renal and vascular outcomes. Details of this study have been described elsewhere. In brief, 8592 individuals, sampled from the general population of Groningen, the Netherlands, underwent extensive examination between 1997 and 1998. The four follow-up examinations were completed in 2003, 2006, 2008 and 2012 . Included were 3649 subjects for whom GWAS data were available. All subjects gave written informed consent. The PREVEND study was approved by the medical ethics committee of the University Medical Centre Groningen and conducted in accordance with the Helsinki Declaration guidelines.
GRS
Genotyping details for PREVEND were described previously [21] . In brief, genotyping was performed on the Illumina CytoSNP12 v2 chip. Variants were imputed to 1000 G [22], Phase 1 version 3, using Minimac software [23] . Population stratification was assessed by principal component analysis; samples with z-score >3 for any of the first five principal components were excluded, i.e. outlying individuals were removed because of likely divergent ancestry [24] . Samples with a call rate <95%, duplicates and sex discrepancies were excluded. Markers with call rate >95%, Hardy-Weinberg equilibrium P-value !1 Â 10 À5 and minor allele frequency !1% were included. From the resulting GWAS data, we extracted the genotypes of the 53 SNPs that were identified in a recent meta-analysis of GWAS on eGFR crea in European populations [15] . Designated risk alleles were those associated with lower eGFR. Genotypes were represented as continuous allelic dosages from 0 to 2, reflecting an additive model [25] . A weighted GRS was defined as the sum of the risk alleles weighted for their published regression coefficient. Therefore, a higher GRS corresponds to higher susceptibility to impaired kidney function. For ease of interpretation, effects are reported per standard deviation (SD) higher GRS.
Outcome measurements and definition
At each examination, participants collected two consecutive 24-h urine specimens after thorough instruction. Participants were asked to avoid heavy exercise as much as possible before urine collection, and instructed to postpone urine collection in case of urinary tract infection, menstruation or fever. The collected urine was stored cold (4 C) for a maximum of 4 days before handing it in. After this, urine specimens were stored at À20 C. Fasting blood samples were obtained and stored at À80 C. Measurement of serum creatinine was performed by an enzymatic method on a Roche Modular analyser using reagents and calibrators from Roche (Roche Diagnostics, Mannheim, Germany), with intra-and inter-assay coefficients of variation of 0.9% and 2.9%, respectively. Serum cystatin C concentration was measured by a Gentian cystatin C Immunoassay (Gentian AS, Moss, Norway) on a Modular analyser (Roche Diagnostics). Cystatin C was calibrated directly using the standard supplied by the manufacturer (traceable to the International Federation of Clinical Chemistry Working Group for Standardization of Serum Cystatin C) [26] The intra-and inter-assay coefficients of variation were <4.1% and <3.3%, respectively. Urinary albumin concentration (UAC) was measured by nephelometry with a lower threshold of detection of 2.3 mg/L, and intra-and inter-assay coefficient of variation of 2.2% and 2.6%, respectively (Dade Behring Diagnostic, Marburg, Germany). UAC was multiplied by urine volume to obtain a value of UAE in mg/24 h. The two 24-h urinary albumin values of each subject per examination were averaged.
We calculated eGFR crea from serum creatinine and eGFR cysc from serum cystatin C, using the corresponding Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations [19] . We defined CKD crea as eGFR crea <60 mL/min/1.73 m 2 , CKD cysc as eGFR cysc <60 mL/min/1.73 m 2 , and CKD UAE as UAE !30 mg/24 h. Incident cases were those free of CKD at baseline who developed CKD during follow-up. In secondary analyses, we used the CKD-EPI equation for both serum creatinine and cystatin C to calculate eGFR crea-cysc [27] . Furthermore, a definition of CKD based on KDIGO guidelines (CKD KDIGO , eGFR crea-cysc <60 mL/min/1.73 m 2 and/or UAE !30 mg/24 h) was used [28] .
Covariates
We selected the following renal risk factors as covariates: age, sex, body mass index [BMI, weight/height 2 (kg/m
2 )], current smoking (self-reported yes/no), diabetes (fasting glucose >7.0 mmol/L, non-fasting glucose >11.0 mmol/L, anti-diabetic treatment or self-reported), hypertension (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg, blood pressure-lowering treatment or self-reported), hypercholesterolaemia (total cholesterol !6.21 mmol/L, lipid-lowering treatment or self-reported) and history of cardiovascular disease (CVD, any past cardio/cerebrovascular event or intervention). Covariates were collected at baseline by means of questionnaires, anthropometry and pharmacy records.
Statistical analyses
Analyses were performed using R3.3.1 and SPSS23.0 (IBM Corporation, Armonk, NY, USA). Two-sided significance level for analyses was set at a ¼ 0.05 unless stated otherwise.
Baseline characteristics. Baseline characteristics were examined for the total population. One-way ANOVA, JonckheereTerpstra and v 2 -tests were used to examine linear trends of characteristics across tertiles of GRS. In subsequent analyses, GRS was treated as a continuous variable. We examined ageand sex-adjusted associations of all 53 individual SNPs with baseline eGFR crea and eGFR cysc using ordinary least squares (OLS) regression.
Cross-sectional associations of the GRS with CKD prevalence and baseline eGFR. Logistic regression was used to examine the association of the continuous GRS with baseline CKD crea . We adjusted for covariates by adding incremental groups of covariates in order to distinguish confounding effects of demographics and risk factors. Group 1 consisted of age and sex; Group 2 additionally included BMI, smoking, diabetes, hypertension, hypercholesterolaemia and history of CVD.
We examined the association of the GRS with continuous eGFR crea using OLS regression. We adjusted for covariates as described above. Analyses were repeated for baseline eGFR cysc and prevalent CKD cysc .
Longitudinal associations of the GRS with CKD incidence and eGFR decline. Cox regression models were used to examine the association of continuous GRS with incident CKD crea . To estimate time to incident CKD crea , we used a midpoint imputation technique. In this analysis, we corrected for baseline eGFR crea in addition to the previously listed renal risk factors. Subjects were censored at death or date of last visit.
Linear mixed effects (LME) analysis was performed to examine the association of the GRS with eGFR decline. We modelled eGFR crea as a function of time since baseline (per year). We specified a model with random intercept, random coefficient for time and unstructured covariance matrix. The GRS, time and covariates were included as fixed effects. A two-way interaction term between GRS and time was introduced to assess whether eGFR crea decline differed by values of the GRS.
Analyses were repeated with the outcomes eGFR cysc decline and incident CKD cysc .
Associations with UAE. We repeated the cross-sectional and longitudinal analyses described above to examine associations of a GRS with renal outcomes based on elevated UAE. Continuous UAE was transformed by its natural logarithm to approach normality [ln(UAE)], in OLS regression and LME analyses.
Secondary analyses. We repeated all analyses using eGFR crea-cysc and CKD KDIGO as outcome. Furthermore, we constructed two alternative GRS. The first alternative GRS comprised 49 SNPs that were significant in the meta-analysis by Gorski et al. [14] , with the second alternative comprising all 63 SNPs identified in either the Pattaro (53 SNPs) or the Gorski study (10 additional SNPs).
R E S U L T S
Baseline characteristics
Baseline characteristics of the 3649 subjects are presented in Table 1 . In univariable analyses, a higher tertile for the GRS was associated with: higher serum creatinine and cystatin C levels (P trend < 0.001); higher prevalence of CKD crea (P trend ¼ 0.002) and CKD cysc (P trend ¼ 0.01); lower eGFR crea (P trend < 0.001) and lower eGFR cysc (P trend < 0.001); and lower UAE (P trend < 0.001). No associations with CKD UAE were found. We found no associations with age, sex, BMI, smoking status, diabetes, hypertension, hypercholesterolaemia or history of CVD.
Details of the 53 SNPs used in the calculation of the GRS and age-and sex-adjusted estimates of their association to baseline eGFR crea , baseline eGFR cysc and ln(UAE) are listed in Supplementary Table S1A . Out of 53 SNPs, 22 reached nominal significance (one-sided P < 0.05), while three were significant when a Bonferroni correction for 53 tests (P < 9.4 Â 10 À4 ) was applied. Supplementary Figure S2 presents a plot of age-and sex-adjusted regression coefficients. These coefficients were obtained by OLS regression of individual SNPs on either eGFR crea or eGFR cysc . Correlation between the regression coefficients on eGFR crea and eGFR cysc was moderate (Pearson r ¼ 0.51, P < 0.001). The total least squares regression line showed fair agreement with the line of identity.
Cross-sectional associations of the GRS with CKD prevalence and baseline eGFR
We present cross-sectional results in Table 2 , P < 0.001] were smaller but showed a similar trend compared to those for creatinine-estimated outcomes. Estimates of the effect sizes of the GRS on both eGFR crea and eGFR cysc remained stable during incremental covariate adjustment.
Longitudinal associations of the GRS with CKD incidence and eGFR decline
We present longitudinal results in Table 3 . A higher GRS was associated with higher incidence of CKD crea after adjustment for known renal risk factors [adjusted hazard ratio (HR) (95% CI) 
Association of the GRS with UAE
Results of analyses on UAE are presented in Tables 2 and 3 Analyses with 24-h urinary albumin-to-creatinine ratio (UACR) as outcome yielded similar results (data not shown).
Secondary analyses
Associations of the GRS with eGFR crea-cysc were consistent with those of the GRS with eGFR crea and eGFR cysc . We found no cross-sectional or longitudinal association of the GRS with CKD KDIGO (Tables 2 and 3) . Two alternative GRS, based on 49 SNPs (GRS 1000G-49 ) and 63 SNPs (GRS 1000G-63 ), were evaluated. Individual SNP-effects of these GRS are listed in Supplementary Table S1B. The GRSs showed similar but slightly weaker associations compared with our main GRS (Supplementary Table S3-S7).
D I S C U S S I O N
In this population-based, longitudinal cohort study, we evaluated the effects of a GRS comprising 53 eGFR crea SNPs on kidney outcomes. To this end, we tested cross-sectional and longitudinal associations of this GRS with CKD crea and eGFR crea and compared these associations to those with CKD cysc and eGFR cysc . Cross-sectional associations of the GRS with the kidney outcomes, CKD crea and eGFR crea , were modest but robust, corroborating the literature. In longitudinal Table 2 . Cross-sectional associations of the GRS with selected kidney outcomes at baseline analyses, we observed no associations with kidney function decline. The GRS was associated with incidence of CKD crea , but this was likely due to lower baseline eGFR rather than accelerated kidney function decline. In comparison with associations with eGFR crea , associations with eGFR cysc were smaller but showed a similar trend. Higher GRS was not associated with kidney damage markers. Furthermore, all associations of the GRS with kidney outcomes were independent of renal risk factors. These data suggest that the GRS is a true representation of the genetics underlying kidney function, as opposed to creatinine metabolism, kidney damage or related aetiologies such as hypertension/diabetes. In secondary analyses, we confirmed associations with eGFR crea-cysc , currently the best estimate for kidney function for large population-based studies [19, 29] . We found no association of the GRS with CKD KDIGO as outcome. This is likely due to the fact that this GRS was optimized for eGFR as outcome and not urinary albumin; in our sample, CKD KDIGO was predominantly characterized by elevated urinary albumin rather than diminished kidney function. Two alternative GRS (GRS 1000G-49 and GRS 1000G-63 ) yielded similar results but proved to be slightly less powerful predictors of kidney function and CKD in this sample.
Previously, two similar GRS based on eGFR crea SNPs were investigated in $2500 participants with $11 years of follow-up from the Framingham Heart Study. O'Seaghdha et al. calculated a 16-SNP GRS for eGFR crea [17] . This sample of the Framingham cohort was revisited by Ma et al. [18] , who updated the GRS with 37 additional SNPs, that is, the same 53 as the present study. Both of these GRS were independently associated with incident CKD (eGFR crea <60 mL/min/1.73 m 2 ), although neither of these GRS improved prediction and/or discrimination beyond clinical risk factors (age, sex, BMI, eGFR, hypertension, diabetes, proteinuria). Interestingly, they reported associations of a higher GRS with a higher incidence of CKD to be independent of baseline eGFR, hence an accelerated deterioration of kidney function in those with a higher GRS. Such an effect was also suggested by Böger et al. [30] in a study of eGFR related loci identified by GWAS. In 26 308 individuals of European ancestry, the associations of 16 separate SNPs known at the time with incident CKD were examined. Of these 16 SNPs, six (mapping to UMOD, PRKAG2, LASS2, DAB2, DACH1 and STC1) were significantly (P < 0.05) associated with incident CKD (eGFR <60 mL/min/1.73 m 2 ), even after correction for baseline eGFR. Similar to the findings of O'Seaghdha et al. and Ma et al., this implies that several SNPs associate with eGFR decline. In contrast, in the present study we could not corroborate such an effect on CKD incidence or eGFR decline: the association of GRS with incident CKD was not significant after adjustment for baseline eGFR, and there was no significant association between the GRS and eGFR decline.
A possible explanation for this discrepancy is the potential overestimation of the effect of the GRS by O'Seaghdha et al. and Ma et al. due to the participation of the Framingham Cohort Study in the discovery phase of the meta-analysis [12, 15] . Similarly, overestimation of individual SNP effects may have occurred in the study by Böger et al., given that seven of the eight cohorts participating in that study were part of the discovery GWAS [12] . Such overlap in discovery and validation cohorts might result in inflated effect sizes [31] . The PREVEND study was not part of the original discovery GWAS, ensuring its independence and suitability as a validation cohort for evaluation of a GRS based on eGFR crea SNPs. This potential overestimation possibly also explains that in our study, the GRS explained only 1.66% of variance of baseline eGFR crea , whereas in the original GWAS, the explained variance of eGFR crea by the combined loci was 3.22% [15] .
Notwithstanding these discrepancies, the combined data suggest that the genetics underlying kidney function are, at least partly, distinct from that underlying kidney function decline and/or kidney disease susceptibility. Our results indicate that a GRS based on cross-sectional GWAS results on kidney function is not clinically applicable (e.g. in the prediction of CKD risk). A GRS would be more applicable if SNPs associated with kidney function decline and/or CKD incidence were used, as these would likely better represent disease susceptibility. Unfortunately, there is a paucity of data on genetic loci associated with kidney function decline or CKD incidence. To the best of our knowledge, only one study by Gorski et al. performed a GWAS for kidney function decline phenotypes [32] . In this study, only one SNP mapping to UMOD (which was also implicated in prior GWAS on cross-sectional eGFR crea ) was significantly associated with eGFR change in the general population, while two novel loci, CDH23 and GALNT15/ GALNT11, were only suggestively associated with eGFR change in CKD patients, and rapid decline in the general population, respectively. To benefit clinical applicability, we argue that future GWAS should focus on disease susceptibility genes, i.e. loci associated with eGFR decline and/or CKD incidence.
We found a higher GRS to be associated with lower UAE, i.e. lower risk of kidney damage, which is surprising for two reasons. First, a prior family study, using bivariate variance component linkage analysis techniques, found a low genetic correlation between eGFR and UACR (r g ¼ 0.002 in African Americans, not reported for European Americans) [5] . Secondly, there is no overlap in genome-wide significant markers for eGFR and albuminuria in the general population [33, 34] . Due to this apparent lack of genetic overlap, it is believed that eGFR and albuminuria have distinct genetic underpinnings. To our knowledge, we are the first to observe this counterintuitive association with the updated 53-SNP GRS. Although the correlation between the GRS and ln(UAE) was weak (r ¼ À0.043), it is unlikely to be a chance finding: in an earlier study by Ellis et al. a weighted GRS (comprising 16 SNPs associated with eGFR crea ) was associated with both lower eGFR and with lower UACR [35] . The authors attributed this effect to the A-allele of rs17319721, an SNP mapping to SHROOM3, because exclusion of this SNP from their GRS attenuated the effect on UACR. In previous GWAS, the SHROOM3 SNP was found to be associated with eGFR crea [12] , and suggestively with UACR (P ¼ 7.0 Â 10 À7 ) [15, 33, 34] . In the present study, exclusion of this SNP from the updated GRS did not attenuate the effect (data not shown). Therefore, it is possible that, in addition to SHROOM3, other loci discovered in the recent meta-analysis on eGFR crea might have pleiotropic effects on both eGFR and albuminuria. We therefore performed a query in LDHub v1.3.1, a platform for LD-score regression which uses original GWAS summary statistics [36, 37] . LD Hub showed a modest genetic correlation between eGFR crea and UACR (r g ¼ 0.388, P < 0.001), and a suggestive genetic correlation between eGFR cysc and UACR (r g ¼ 0.195, P ¼ 0.087), in the same direction as our findings (i.e. higher eGFR $higher UACR). These correlations suggest that there is at least partial overlap in the genetics underlying eGFR and albuminuria. Addressing the question of pleiotropy is beyond the scope of the present study and requires dedicated analysis in larger samples.
A number of SNPs identified in the GWAS on eGFR crea may be linked to loci related to creatinine production or secretion, hence not with kidney function per se [38] . We therefore examined two SNPs mapping to loci known to be related to creatinine metabolism: rs2467853, which maps to the creatinine production locus GATM [39] , and rs316009, which maps to the creatinine secretion locus SLC22A2 [40] . For both SNPs, we observed an inconsistency in the direction of effect for baseline eGFR crea and eGFR cysc (see Supplementary Table S1A ), suggesting that these loci are indeed not related to kidney function. Exclusion of these SNPs led to a slightly improved GRS: effects of this GRS on eGFR crea and eGFR cysc more closely resembled each other than those of the main GRS, although this improvement was only slight (data not shown). Our conclusions, therefore, remain unchanged. Future functional studies may investigate other presumptive creatinine-related loci. The exclusion of such loci may result in a GRS that more accurately reflects genetic predisposition to kidney function.
To our knowledge, we are the first study to examine the association between a GRS comprising 53 SNPs and eGFR decline. Strengths of this study include the availability of serially measured creatinine and cystatin C, as well as two 24-h urinary albumin measurements at each examination, during a considerable follow-up duration of 11 years. A major strength of PREVEND is its independence from the discovery GWAS that identified the 53 SNPs used in the GRS, resulting in unbiased effect estimates of the GRS. Given that participants of the PREVEND GWAS sample are of European ancestry, we cannot generalize to other ethnicities. Finally, we could not calculate genetic correlations between eGFR levels and eGFR decline as GWAS summary results for eGFR decline were currently not available.
In conclusion, a GRS comprising 53 SNPs showed modest but robust associations with cross-sectional CKD outcomes based on eGFR crea . These associations were confirmed with eGFR cysc , which highlights the potential usefulness of a GRS as a representation of the genetics underlying kidney function. However, no longitudinal associations with incident CKD or eGFR decline were found. Given these results, we question the clinical utility of cross-sectional GWAS results on kidney function. We suggest that future GWAS specifically examine genetic associations with eGFR decline and/or CKD incidence. These GWAS may identify loci that, when incorporated into a GRS, will improve the clinical utility of this score, e.g. in predicting onset of CKD.
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C O N F L I C T O F I N T E R E S T S T A T E M E N T
None declared. Methods. We performed an analysis of the static (baseline adiponectin levels) and dynamic (fluctuations in adiponectin levels) interactions of serum adiponectin with the FGF23 response to paricalcitol and placebo in the setting of a double-blind, randomized clinical trial in chronic kidney disease (CKD) patients (NCT01680198). Results. As compared with placebo, VDR activation by paricalcitol markedly increased serum FGF23 levels (P < 0.001), and such an increase was amplified in patients in the 4th adiponectin quartile as compared with other quartiles (P ¼ 0.009) while no such an effect was noted in the placebo group (P ¼ 0.49). Both baseline adiponectin (P for interaction ¼ 0.009) and fluctuations in
